Floatz logo

kfa115

Carcinoma, Thymic

Novartis PharmaceuticalsPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Carcinoma, Thymic cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 2B
Fludarabine
Beijing Biotech
Phase 2B
Regorafenib
Istituto Clinico Humanitas
Phase 2B
Busulphan
Roswell Park Cancer Institute
Phase 2B
CYCLOSPORIN A
Roswell Park Cancer Institute
Phase 2B

View all 26 →

Same molecule, other indications

kfa115 is also rated in:

ovarian carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
gastroesophageal cancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →